[Specific features of cellular immunity of pulmonary tuberculosis in patients with diabetes mellitus].

PubWeight™: 0.76‹?›

🔗 View Article (PMID 9503939)

Published in Probl Tuberk on January 01, 1997

Authors

M A Karachunskiĭ, V Ia Gergert, O B Iakovleva

Articles by these authors

[L-transformation of the mycobacterial population in the process of treating patients with newly detected destructive pulmonary tuberculosis]. Probl Tuberk (1980) 0.87

[Various approaches to tuberculosis diagnosis in patients with hemoblastosis]. Ter Arkh (2002) 0.82

[Tuberculosis in patients with hemoblastoses]. Probl Tuberk (2002) 0.78

[Clinical picture of tuberculosis with concomitant hemoblastoses]. Ter Arkh (2004) 0.77

[Clinical aspects of pulmonary tuberculosis in patients with borderline disorders of carbohydrate metabolism]. Probl Tuberk (1993) 0.77

[Tuberculous IgE antibodies. Part II. Study of its concentrations in different forms of tuberculosis]. Probl Tuberk (2002) 0.77

[Anti-tuberculous IgE antibodies. I. Immunodominant antigens]. Probl Tuberk (2002) 0.77

[Effectiveness of antitubercular chemotherapy combined with corticosteroids and immunomodulators]. Probl Tuberk (1990) 0.76

[Cytokines in tuberculosis]. Vestn Ross Akad Med Nauk (1995) 0.76

[Changes in carbohydrate metabolism in patients with tuberculosis]. Vestn Ross Akad Med Nauk (1995) 0.75

[Natural killer cells in patients with pulmonary tuberculosis]. Biull Eksp Biol Med (1991) 0.75

[Clinico-radiographic peculiarities of nonspecific pneumonia developing against a background of posttuberculous changes]. Probl Tuberk (1976) 0.75

[Specific immunity indices in effective and less effective chemotherapy of tuberculosis]. Probl Tuberk (1973) 0.75

[Clinical symptoms and course of tuberculous meningitis in children: isolation of L-forms from the cerebrospinal fluid]. Probl Tuberk (1990) 0.75

[New tuberculin tests in detecting latent activity of tuberculous process]. Probl Tuberk (1977) 0.75

[Pulmonary tuberculosis and diabetes mellitus]. Probl Tuberk (1990) 0.75

[A new method of the evaluation of lymphocytes and monocytes during immune response in patients with tuberculosis and sarcoidosis]. Probl Tuberk (1991) 0.75

[Features of isoniazid activation in patients with tuberculosis and diabetes mellitus]. Probl Tuberk (2001) 0.75

[Screening for borderline disorders of carbohydrate metabolism in patients with pulmonary tuberculosis]. Probl Tuberk (1994) 0.75

[Effect of use of bone marrow cells in therapy for experimental tuberculosis]. Probl Tuberk Bolezn Legk (2006) 0.75

[The combined use of corticosteroids and immunostimulators in the combination therapy of patients with tuberculosis of the lungs (methodologic recommendations]. Probl Tuberk (1992) 0.75

[Characteristics of a Mycobacterium population growing in pulmonary tuberculomas]. Probl Tuberk (1987) 0.75

[Zakharin as a phthisiologist]. Probl Tuberk Bolezn Legk (2005) 0.75

[Treatment of immunodeficient conditions caused by viral infection with the Soviet immunomodulator kemantan in patients with pulmonary tuberculosis]. Probl Tuberk (1991) 0.75

[Dynamics of L-form Mycobacteria excretion in the treatment of patients with newly diagnosed destructive pulmonary tuberculosis]. Probl Tuberk (1978) 0.75

[Individual approaches to complex treatment of disseminated tuberculous processes in adolescents]. Probl Tuberk Bolezn Legk (2006) 0.75

[Characteristics of chemotherapy of pulmonary tuberculosis and its effectiveness in patients with diabetes mellitus]. Probl Tuberk (1991) 0.75

[Molecular epidemiology of tuberculosis]. Probl Tuberk Bolezn Legk (2007) 0.75

[Efficacy of treating patients with disseminated forms of destructive pulmonary tuberculosis using chemical preparations and T-activin]. Probl Tuberk (1989) 0.75

[Characteristics of qualitative changes in the Mycobacteria population during the treatment of middle-aged and elderly patients with newly detected pulmonary tuberculosis]. Probl Tuberk (1990) 0.75

[Immunological and biochemical indicators in the evaluation of the effectiveness of a complex treatment of infiltrative pulmonary tuberculosis]. Probl Tuberk (1984) 0.75

[Complex therapy of patients with destructive pulmonary tuberculosis using chemotherapeutic agents combined with T-activin]. Probl Tuberk (1986) 0.75

[Quantitative, spectral, and serodiagnostic characteristics of antimycobacterial IgG, IgM, and IgA antibodies in patients with pulmonary tuberculosis]. Probl Tuberk Bolezn Legk (2006) 0.75

[Clinical symptoms and course of pulmonary tuberculosis in patients with various types of diabetes mellitus]. Probl Tuberk (1993) 0.75

[Efficiency of an intensive stage of chemotherapy for tuberculosis in elderly and senile patients]. Probl Tuberk Bolezn Legk (2004) 0.75

[Pulmonary tuberculosis after bilateral nephrectomy]. Probl Tuberk (1991) 0.75

[The activity of immunocompetent cells and macrophages in pulmonary sarcoidosis (in comparison to tuberculosis)]. Probl Tuberk (1996) 0.75

[Tuberculosis in HIV infection]. Probl Tuberk (2000) 0.75

[Value of the immunological tests in the diagnosis of adverse effects of tuberculostatic therapy]. Probl Tuberk (1980) 0.75

[Immunological indicators in newly detected pulmonary tuberculosis with different degree of infiltration]. Probl Tuberk (1981) 0.75

[Intensive chemotherapy tolerance in old patients with pulmonary tuberculosis]. Probl Tuberk Bolezn Legk (2004) 0.75

[Pathogenetic therapy of pulmonary tuberculosis]. Probl Tuberk (1980) 0.75

[Tuberculin-BCG therapy in combined treatment of patients with pulmonary tuberculosis]. Probl Tuberk (1995) 0.75

[Evaluation of the course and prognosis of tuberculosis using immunological tests]. Probl Tuberk (1976) 0.75

[Comparative effectiveness of different methods for the microbiological study of resected pulmonary tuberculomas]. Zh Mikrobiol Epidemiol Immunobiol (1987) 0.75

[Migration inhibition reaction of sensitized leukocytes and activity of the tubercular process]. Zh Mikrobiol Epidemiol Immunobiol (1972) 0.75

[Effect of rifampicin on the L transformation of a mycobacterial population in patients with destructive pulmonary tuberculosis]. Probl Tuberk (1986) 0.75

[L-forms of Mycobacterium tuberculosis during chemotherapy of patients with chronic destructive pulmonary tuberculosis]. Probl Tuberk (1983) 0.75

[Isolation of mycobacteria L forms as a prognostic criterion of recurrence and aggravation of tuberculosis in patients with extended residual tuberculous lesions of the lungs]. Probl Tuberk (1989) 0.75

[Changes of immune and non-specific reactivity in patients with chronic suppurative obstructive bronchitis in comprehensive treatment with thymogen]. Probl Tuberk (1994) 0.75

[Mycobacterial antigens and tuberculosis antibodies in the blood and pleural exudate of patients with tuberculous pleurisy]. Probl Tuberk (1999) 0.75

[Clinical picture and course of chronic destructive pulmonary tuberculosis in patients secreting L forms of the causative agent]. Probl Tuberk (1985) 0.75

[Immunologic and non-specific reactivity in patients with chronic suppurative obstructive bronchitis and its effect on the course of disease]. Probl Tuberk (1994) 0.75

[Clinico-bacteriological characteristics of tuberculosis of peripheral lymph nodes]. Probl Tuberk (1984) 0.75

[Immunological studies in differential diagnosis of tuberculosis and sarcoidosis]. Klin Med (Mosk) (1977) 0.75

[Results of controlled clinical trials of intensive isoniazid therapy]. Probl Tuberk (1980) 0.75

[Characteristics of clinical features of tuberculosis of the peripheral lymph nodes with the isolation of L forms of Mycobacterium tuberculosis]. Probl Tuberk (1983) 0.75

[Criteria of dispensary registration of patients in the O group]. Probl Tuberk (1979) 0.75

[T-lymphocyte subpopulations in sarcoidosis]. Probl Tuberk (1984) 0.75

[Distribution of HLA antigens in patients with tuberculosis and healthy individuals in the Tatar population]. Probl Tuberk Bolezn Legk (2004) 0.75

[Change in the function of the kidneys and the elimination of antitubercular preparations with their side effects in patients with pulmonary tuberculosis]. Probl Tuberk (1975) 0.75

[Relation between the dynamics of immunologic indices and newly detected pulmonary tuberculosis patients and the timing of the end of bacterial isolation and the closure of destruction cavities]. Probl Tuberk (1982) 0.75

[Pulmonary tuberculosis in patients with different types of diabetes mellitus]. Probl Tuberk (2002) 0.75

[Immunology and pathogenesis of sarcoidosis]. Probl Tuberk (1982) 0.75

[Diagnosis of chronic inflammatory diseases in adolescents]. Akush Ginekol (Mosk) (1982) 0.75

[Clinical characteristics of newly detected destructive pulmonary tuberculosis in patients excreting mycobacterial L forms]. Probl Tuberk (1980) 0.75

[Tuberculosis in patients with diabetes mellitus: present-day problems]. Probl Tuberk Bolezn Legk (2006) 0.75

[Comparative evaluation of determining T lymphocyte subpopulations by different methods]. Vrach Delo (1988) 0.75

[Phenotypic and functional analysis of blood lymphocytes and pathological focus in patients with pulmonary tuberculosis]. Probl Tuberk (1995) 0.75

[Body reactivity characteristics of pulmonary tuberculosis patients with negative reactions to tuberculostatic preparations]. Probl Tuberk (1980) 0.75

[Tactics of diabetes mellitus compensation in patients with pulmonary tuberculosis]. Probl Tuberk (1991) 0.75

[Cytokines in immunopathogenesis of pulmonary tuberculosis]. Probl Tuberk (1995) 0.75

[Increasing the effectiveness of microbiological diagnosis of limited nondestructive pulmonary tuberculosis]. Probl Tuberk (1989) 0.75

[Experience with kipferon use in the treatment of patients with pulmonary tuberculosis]. Probl Tuberk (2002) 0.75

[Effectiveness of an intensive chemotherapy stage in new cases of pulmonary tuberculosis and diabetes mellitus]. Probl Tuberk Bolezn Legk (2004) 0.75

[Levamisole in the treatment of late middle-aged pulmonary tuberculosis patients]. Probl Tuberk (1987) 0.75

[Tuberculosis in leukemia patients]. Probl Tuberk (2001) 0.75

[Increased delayed type hypersensitivity and immunity to tuberculosis]. Probl Tuberk (1972) 0.75

[Use of T-activin in patients with sarcoidosis]. Probl Tuberk (1990) 0.75

[Experimental study of delayed-type hypersensitivity and antitubercular immunity]. Biull Eksp Biol Med (1971) 0.75

[Dynamics of the indicators of blast transformation reaction in complex chemo- and tuberculin therapy of tuberculosis]. Probl Tuberk (1975) 0.75

[The immunomodulating action of cyclosporin A in vitro and in vivo on the lymphocytes of patients with alveolitis]. Probl Tuberk (1996) 0.75

[Immunology of tuberculosis: current status]. Vestn Ross Akad Med Nauk (1999) 0.75

[Immunological status of newly detected patients with destructive pulmonary tuberculosis]. Probl Tuberk (1979) 0.75

[Morphologic changes in experimental reimplantation and homotransplantation of the lungs]. Arkh Patol (1968) 0.75

[Intensive chemotherapy of new-onset pulmonary tuberculosis in patients with diabetes mellitus and in elderly and senile patients]. Probl Tuberk Bolezn Legk (2008) 0.75

[The procedure for the differentiated hypoglycemic therapy of diabetics hospitalized for pulmonary tuberculosis. The Central Research Institute of Tuberculosis of the Russian Academy of Medical Sciences, Moscow]. Probl Tuberk (1996) 0.75

[Immunological bases of tuberculin therapy in combined treatment of patients with pulmonary tuberculosis]. Probl Tuberk (1994) 0.75

[Liver function at the stage of intensive tuberculosis treatment of patients with diabetes mellitus]. Probl Tuberk (2000) 0.75

[L forms of Mycobacterium tuberculosis in chronic pleural empyema in tuberculosis patients]. Probl Tuberk (1981) 0.75

[Sarcoidous pneumonia]. Probl Tuberk (1985) 0.75

[Screening of disorders of carbohydrate metabolism in patients with active pulmonary tuberculosis]. Probl Tuberk (1992) 0.75

[Effect of acute respiratory viral infection on the indicators of immunity in patients with pulmonary tuberculosis]. Probl Tuberk (1990) 0.75

[Improving the efficacy of tuberculosis immunodiagnosis using anti-human IgG monoclonal antibodies]. Klin Lab Diagn (1999) 0.75

[Immunological methods of examination in differential diagnosis of various lesions of the middle lobe and lingular segments of the lungs]. Ter Arkh (1978) 0.75

[Specific in vitro transformation of peripheral blood lymphocytes in tuberculosis]. Probl Tuberk (1973) 0.75

[Microbiological research on fluid obtained during bronchoalveolar lavage of patients with circumscribed pulmonary tuberculosis]. Probl Tuberk (1988) 0.75